Can sofosbuvir and velpatasvir (Epclusa) treat cirrhosis?

Sofosbuvir and velpatasvir(Epclusa)combination is a pan-genotype, pan-fibrosis, protease inhibitor-free regimen indicated for treatment12 weeks in combination with ribavirin in adult and pediatric patients 3 years and older with chronic hepatitis C virus (HCV) 1 to 6 infection, no cirrhosis or compensated cirrhosis, HCV/HIV-1 co-infection, or decompensated cirrhosis. HCV can be an opportunistic infection (OI) of HIV.

The combination of sofosbuvir and velpatasvir is an agent used to prevent or treat viral diseases. Some of the ways they may work include preventing viral replication by inhibiting viral DNA polymerase, binding to specific cell surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking later stages of viral assembly. If you have been infected with hepatitis B (a virus that infects the liver and can cause severe liver damage) but do not have any symptoms of the disease, taking sofosbuvir or velpatasvir combination may increase the risk that the infection will become more serious or life-threatening and symptoms will develop. Tell your doctor if you have ever been infected with hepatitis B virus.

The original drug of sofosbuvir and velpatasvir has been launched in China and has entered the scope of Class B medical insurance. The domestic trade name is protonsa, and the specification (400mg+100mg)*28 tablets is priced at about 4,000 yuan per box. The original drug of sofosbuvir and velpatasvir has also been launched overseas. There are also generic drugs of sofosbuvir and velpatasvir produced in other countries. The price of the specification (400mg + 100mg) * 28 tablets produced by Everest Pharmaceutical Factory in Bangladesh is about 850 yuan per box (the price may fluctuate due to the exchange rate). The generic drugs produced abroad are basically the same as the original drugs at home and abroad.